Advanced glycation endproducts (AGEs) have been implicated in the
pathogenesis of a variety of debilitating diseases such as diabetes,
atherosclerosis, Alzheimer's and rheumatoid arthritis, as well as in the
normal aging process. Seven compounds are here reported to be active in
breaking AGE-protein cross-links. These compounds are
1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid] (LR102);
4-[(3,5-dichlorophenylureidophenoxyisobutyryl]-4-aminobenzoic acid (LR99);
L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine] (LR20);
4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxy
lic acid (LR23); methylene bis [4,4'-(2-chlorophenylureidophenoxyisobutyric
acid)] (LR90); 5-aminosalicylic acid (5-ASA); and metformin. These
compounds may be used to reverse the debilitating effects of those
diseases in which AGEs are formed.
Los endproducts avanzados del glycation (edades) han estado implicados en la patogenesia de una variedad de enfermedades debilitantes tales como diabetes, atherosclerosis, Alzheimer y artritis reumatoide, tan bien como en el proceso normal del envejecimiento. Siete compuestos aquí se divulgan para ser activos en romper reticulaciones de la Edad-protei'na. Estos compuestos son el ácido 1,4-benzene-bis[4-methyleneaminophenoxyisobutyric ] (LR102); ácido 4-[(3,5-dichlorophenylureidophenoxyisobutyryl]-4-aminobenzoic (LR99); L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine ] (LR20); 4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxy ácido lic (LR23); bis del metileno [ ácido 4,4'-(2-chlorophenylureidophenoxyisobutyric) ] (LR90); ácido 5-aminosalicylic (5-ASA); y metformin. Estos compuestos se pueden utilizar para invertir los efectos debilitantes de esas enfermedades en las cuales se formen las edades.
